Company: BSX
Filing Date: 2025-11-03
Form Type: 10-Q
Source: 0000885725-25-000050
Chunk: 78

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-11-03
Form: 10-Q
Item: Part I, Item 1
Chunk 78
---
) Calculated as Net sales of reportable segments less Segment expenses. Three Months EndedSeptember 30,Nine Months EndedSeptember 30,Depreciation expense (in millions)2025202420252024MedSurg$29 $27 $84 $79 Cardiovascular89 75 250 211 Consolidated depreciation expense$117 $102 $334 $290 As ofTotal assets (in millions)September 30, 2025December 31, 2024MedSurg$3,392 $3,093 Cardiovascular7,799 7,084 Total assets of reportable segments11,191 10,177 Goodwill18,214 17,089 Other intangible assets, net7,162 6,684 All other corporate assets6,140 5,446  $42,707 $39,395 

35

Table of Contents

As ofLong-lived assets (in millions)September 30, 2025December 31, 2024U.S.$1,812 $1,461 Ireland707 631 Costa Rica593 530 Other countries683 672 Property, plant and equipment, net3,795 3,294 Goodwill18,214 17,089 Other intangible assets, net7,162 6,684 Operating lease right-of-use assets in Other long-term assets495 449  $29,665 $27,516 

NOTE K – REVENUE We generate revenue primarily from the sale of single-use medical devices and present revenue net of sales taxes within our accompanying unaudited consolidated statements of operations. Our business structure is organized into five operating segments. The following tables disaggregate our revenue from contracts with customers by business unit and geographic region (in millions). Generally, we allocate revenue from contracts with customers to geographic regions based on the location where the sale originated.Three Months Ended September 30,20252024BusinessesU.S.Int'lTotalU.S.Int'lTotalEndoscopy$462 $285 $747 $417 $261 $678 Urology511 171 682 379 153 532 Neuromodulation230 63 293 211 57 268 MedSurg1,202 519 1,722 1,007 472 1,479 Interventional Cardiology Therap